Duligotuzumab, a bsAb directed against EGFR and HER3, which is currently in phase Ib for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (28, 29), was used as a control. Here, EGFR is linked to metastatic squamous cell carcinoma.